Non-Small Cell Lung Cancer News

News

FDA Approved Lazertinib Plus Amivantamab for Advanced Non-Small Cell Lung Cancer With EGFR Mutations

08/20/2024

The FDA has approved lazertinib plus amivantamab for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations.

The FDA has approved lazertinib...

08/20/2024

Oncology

News

FDA Grants Approval to Neoadjuvant/Adjuvant Durvalumab for Patients With Resectable Non-Small Cell Lung Cancer

08/16/2024

Stephanie Holland ;

The FDA has approved durvalumab plus a platinum-containing regimen followed by surgery and single-agent durvalumab for adult patients with resectable non-small cell lung cancer with no known EGFR mutations or ALK rearrangements.

The FDA has approved durvalumab...

08/16/2024

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

News

First-Line Amivantamab Plus Lazertinib Superior to Osimertinib Among Patients With Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

07/18/2024

Stephanie Holland ;

Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.

Results from the phase 3...

07/18/2024

Oncology

News

Perioperative Nivolumab Prolonged Event-Free Survival Compared to Perioperative Chemotherapy Among Patients With Resectable Non-Small Cell Lung Cancer

07/15/2024

Stephanie Holland ;

Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.

Results from the phase 3...

07/15/2024

Oncology

News

Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer

06/26/2024

Brandon Twyford

Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...

Researchers conducted a study on...

06/26/2024

Journal of Clinical Pathways

FDA Approval

FDA Approves Osimertinib Plus Platinum-Based Chemotherapy For Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer

02/21/2024

Stephanie Holland ;

Based on results from the phase 3 FLAURA 2 trial, the FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 19 deletions or exon 21 L858R...

Based on results from the phase...

02/21/2024

Oncology

News

Addition of Canakinumab to First-Line Pembrolizumab Plus Chemotherapy Did Not Prolong Survival Outcomes Among Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

01/09/2024

Stephanie Holland ;

According to results from the CANOPY-1 trial, the addition of canakinumab to first-line pembrolizumab plus chemotherapy did not prolong PFS or OS among patients with advanced or metastatic non-small cell lung cancer who do not harbor ALK or...

According to results from the...

01/09/2024

Oncology

News

Tracking Cost of Care Discussions Between Physicians and Patients with NSCLC and Melanoma

10/30/2023

Grace Taylor , MS, MA;

Robin Yabroff, PhD, MBA, and Michael T. Halpern, MD, PhD, MPH, examine the documentation of cost of care discussions between physicians and patients with non–small cell lung cancer and melanoma.

Robin Yabroff, PhD, MBA, and...

10/30/2023

Journal of Clinical Pathways

News

New Dimensions in Comprehensive Genomic Testing

10/17/2023

Grace Taylor , MS, MA;

Eric Severson, MD, PhD, Labcorp Oncology, examines genomic testing’s role in comprehensive oncology pathways.

Eric Severson, MD, PhD, Labcorp...

10/17/2023

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Non-Small Cell Lung Cancer News

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products